

DEP® radiopharmaceutical data supports patent application

Melbourne, Australia; 2 July 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today announces the filing of a new patent application supporting the use of its proprietary DEP® technology in radioligand therapy (RLT), following encouraging preclinical findings demonstrating a differentiated radiopharmaceutical profile.

Key highlights

- Starpharma's DEP® radiopharmaceutical platform demonstrates improved biodistribution, with enhanced tumour uptake and retention and reduced off-target accumulation
- Consistent data across multiple oncology targets, including HER2, PSMA and EGFR, support DEP® as a modular, broadly applicable radiopharmaceutical platform
- Findings suggest potential for an improved therapeutic window, with efficient tumour delivery and reduced off-target exposure
- New patent application filed covering the use of DEP® dendrimer technology in radioligand therapy, strengthening Starpharma's platform IP position
- Data support the potential for further partnering opportunities across the rapidly growing radiopharmaceutical sector

Radiopharmaceuticals represent one of the fastest-growing areas of precision oncology, with the global market valued at approximately US\$8 billion and expected to grow to ~US\$15 billion by 2030. With strong clinical outcomes driving investment and partnering activity, the sector is attracting significant strategic interest from global pharmaceutical companies.

DEP® radiopharmaceutical platform demonstrates differentiated profile

Achieving effective tumour targeting while minimising off-target toxicity remains a central challenge in radioligand therapy. Current approaches are often constrained by trade-offs between tumour delivery, kidney exposure, and prolonged circulation.

Starpharma's DEP® dendrimer technology is designed to address these limitations through controlled delivery and modified biodistribution profiles.

Across a range of targeted dendrimer radiopharmaceutical constructs, including those directed against HER2, PSMA and EGFR, Starpharma has observed:

- Strong and sustained tumour uptake, with tumour-associated signal evident for a prolonged period post-dose
- Low off-target accumulation, including reduced kidney and systemic exposure
- Rapid blood clearance combined with efficient renal excretion without prolonged kidney retention
- A consistent biodistribution profile across multiple targets

These findings suggest that the DEP® platform may enable delivery of therapeutically relevant radiation doses to tumours while reducing exposure to healthy tissues, supporting the potential for an improved therapeutic window relative to existing radiopharmaceutical approaches.

Commenting on the announcement, Starpharma CEO, Cheryl Maley said:

“These data highlight the potential for our DEP® platform to deliver a differentiated radiopharmaceutical profile, combining strong tumour targeting with reduced off-target exposure.

Radiopharmaceuticals are an exciting and rapidly growing area of oncology, and we believe DEP® is well positioned to address key limitations in current approaches.

The filing of this patent further strengthens our platform IP and supports our strategy to generate value through the development and partnering of multiple DEP® radiopharmaceutical programs.”

Platform approach supports broad radiopharmaceutical opportunity

The consistent biodistribution profile observed across multiple targets highlights the modular nature of the DEP® platform and its applicability across a range of tumour types and targeting approaches.

Unlike conventional radioligand approaches, which can be constrained by either high kidney uptake in the case of peptides and fragments or prolonged systemic exposure in the case of antibodies, DEP® is designed to combine favourable delivery characteristics with tuneable pharmacokinetics.

This platform approach has the potential to support the development of multiple differentiated radiopharmaceutical assets and creates opportunities for parallel partnering programs across different oncology targets.

Together, the consistent cross-target data and new patent application strengthen Starpharma’s position to pursue potential partnering opportunities across the radiopharmaceutical sector.

Starpharma continues to evaluate partnering opportunities with specialist radiopharmaceutical and oncology companies to leverage its DEP® technology in this rapidly evolving sector.

Patent application strengthens strategic IP position

The new patent application covers the use of Starpharma’s DEP® dendrimer technology in RLT and further strengthens the Company’s intellectual property position in radiopharmaceutical drug delivery.

Importantly, the application is expected to support protection of DEP® radiopharmaceutical approaches across multiple targets, reinforcing the Company’s ability to develop and partner a range of differentiated assets within this field.



About Starpharma

Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](#).

Investor & Media Relations

Gabriella Hold
gaby@thecapitalnetwork.com.au

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.